Novartis Accelerates Drug Discovery Timelines Using AI Platforms and Advances Clinical Candidates

Novartis reports that AI tools are shortening drug discovery timelines, allowing earlier candidate selection and reducing laboratory cycles; the company highlighted findings at the Machine Learning in Drug Discovery Symposium 2025, noting faster data integration.

AI models analyze large chemical libraries and predict target interactions, enabling researchers to focus on promising compounds without extensive physical testing; industry analysts say this capability makes AI‑driven drug discovery the next big bet for pharma investment.

Insilico Medicine demonstrates an AI‑driven platform that designs novel molecules, accelerating pre‑clinical phases and claiming cost efficiencies compared with traditional methods; the firm reported several candidates now entering animal testing ahead of schedule.

Clinical study of an AI‑designed drug candidate shows reversal of biological age markers, providing early evidence that computationally generated medicines can achieve measurable health effects and may reshape future therapeutic strategies.